99mTc‐MIBI imaging for prediction of therapeutic effects of second‐generation MDR1 inhibitors in malignant brain tumors
Authors:
Open Access
- 20 August 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 121 (12) , 2637-2645
Abstract
The aim of this study was to explore whether99mTc‐methoxyisobutylisonitrile (99mTc‐MIBI) is suitable to elucidate multidrug resistance and prediction of potentiation of antitumor agents by second‐generation MDR1 inhibitors (PSC833, MS‐209) in malignant brain tumors in rat. Malignant tumor cells (RG2 and C6 gliomas, Walker 256 carcinoma) were incubated with low dose vincristine (VCR) to induce multidrug resistance. MTT assay demonstrated a significant increase of surviving fractions in VCR‐resistant sublines compared to those of drug‐naive cells. Reverse transcriptase polymerase chain reaction revealed higher expression of MDR1 mRNA in VCR‐resistant cells than drug‐naive cells in each line. Volume distribution (Vd) of99mTc‐MIBI was negatively correlated with MDR1 mRNA expression among drug‐naive and VCR‐resistant cells. MDR1 inhibitors decreased surviving fractions and increasedVdof99mTc‐MIBI significantly in VCR‐resistant sublines, whereas MDR1 mRNA expression was unchanged. These findings indicate that99mTc‐MIBI efflux was functionally suppressed by MDR1 inhibitors. Autoradiographic images of99mTc‐MIBI revealed higher uptake in drug‐naive cells at basal ganglia compared with VCR‐resistant cells at the opposite basal ganglia of rats. Oral administration of the second‐generation MDR1 inhibitors significantly increased99mTc‐MIBI accumulation of both tumors. Therapeutic effects of VCR with or without the MDR1 inhibitors were also evaluated autoradiographically using14C‐methyl‐L‐methionine (14C‐Met) and MIB‐5 index.14C‐Met uptake and MIB‐5 index of both tumors treated with VCR following the MDR1 inhibitor treatment significantly decreased compared with tumors treated with VCR alone. Analysis of99mTc‐MIBI accumulation is considered informative for detecting MDR1‐mediated drug resistance and for monitoring the therapeutic effects of MDR1 inhibitors in malignant brain tumors.Keywords
This publication has 46 references indexed in Scilit:
- Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studiesJournal of Neuro-Oncology, 2005
- Technetium-99m Sestamibi Single Photon Emission Computed Tomography Findings Correlated With P-glycoprotein Expression, Encoded by the Multidrug Resistance Gene-1 Messenger Ribonucleic Acid, in Intracranial MeningiomasNeurologia medico-chirurgica, 2003
- Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patientsCancer, 2001
- The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma – a comparative study with 201TlNeuroradiology, 2001
- The Usefulness of Tc-99m MIBI for Evaluating Brain TumorsClinical Nuclear Medicine, 1999
- Preliminary results with technetium-99M MIBI spect imaging in patients with brain tumors: Correlation with histological and neuroradiological diagnoses and therapeutic responseComputerized Medical Imaging and Graphics, 1997
- Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistanceNeurosurgery, 1997
- 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistanceNuclear Medicine Communications, 1995
- Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.Proceedings of the National Academy of Sciences, 1987